A rare case of scapular metastasis from bronchogenic carcinoma with ipsilateral malignant pleural effusion

Sir,

A large number of the patients with lung cancer present with symptoms due to metastases caused by hematogenous dissemination or lymphatic spread of tumor cells to the distant sites, and the prognosis is poor in these patients. Approximately one third of patients of lung cancer present with symptoms due to metastases outside the thorax. Lungs, liver, bones, lymph nodes, pleura, pericardium, adrenal glands, brain, and skin are common sites for metastases of bronchogenic carcinoma. Lung cancer can metastasize to any bone, but the axial skeleton and proximal long bones are most commonly affected. Among the axial skeleton, vertebrae, especially thoracic spine is most commonly involved, whereas proximal femur is the most common site for metastases to long bones in lung cancer. But scapular metastasis is found to be rare in bronchogenic carcinoma.

A 40-year-old non-smoker female presented with progressively increasing dull aching pain over right shoulder for last 2 months. This was followed by development of left-sided pleuritic chest pain with heaviness, dyspnea on exertion and productive cough for last 1 month. The shoulder pain was aggravated at night, relieved by non-narcotic analgesics. There was no history...
Due to metastases. Ultrasound of abdomen and CECT brain revealed no abnormality. Hence, the diagnosis was poorly differentiated squamous cell carcinoma of left lung complicated by ipsilateral, encysted, malignant pleural effusion and metastases to right scapula.

80% cases of bone metastases are due to prostate, breast, and lung cancers. Other important primary sites for bone metastases are kidney, bladder, and thyroid. Vertebrae, proximal femur, pelvis, ribs, sternum, proximal humerus, and skull are affected in descending order of frequency. Scapula is rarely involved. Bone metastases in lung cancers are usually caused by hematogenous dissemination of tumor cells. Bone metastases may be asymptomatic or may present with bone pain, swelling, spinal cord compression with paraplegia, and pathologic fracture. Hypercalcemia is mainly found in cases of bone destruction. Bone pain is the most common symptom for metastatic bone tumors, may sometimes be the first presentation (25%) without symptoms of lung tumor itself, and adenocarcinomas are the most common histological types of lung cancers associated with bone metastases. In our case, right shoulder pain due to osteolytic metastasis to scapula was the presenting symptom of non-small cell carcinoma of contralateral lung—a very rare clinical presentation. This pain was followed by development of distressing respiratory symptoms due to tumor itself and ipsilateral pleural effusion.

Bone metastases may be osteolytic due to osteoclast activity or osteogenic, characterized by new bone formation due to osteoblastic activity. Osteolytic lesions (>1 cm) are best detected by plain radiography and associated with hypercalcemia which was noted in our case. Osteogenic lesions may readily be detected using radionuclide bone scan, characterized by increased uptake of radiotracer (Tc⁹⁹) at the site of lesions, and increased bone density or sclerosis is seen on plain radiograph. Osteoblastic lesions are associated with high serum alkaline phosphatase level and may produce hypocalcemia in the extensive lesions. Renal cell carcinomas produce mainly osteolytic lesions, whereas prostate cancers produce predominantly osteoblastic lesions. But, in most cases, metastatic lesions produce combination of these two types, as in lung cancers. In our case, it was predominantly osteolytic lesion involving right scapula which was very much evident on plain radiograph.

![Figure 1: X-ray of right shoulder joint showing an osteolytic lesion in scapula](image1)

![Figure 2: (a) CECT thorax showing right scapular destruction. (b) (Blue Arrow) and left sided lung mass with ipsilateral encysted pleural effusion](image2)
Non-narcotic or narcotic analgesics, local palliative radiotherapy, bisphosphonates (like zoledronic acid) may be helpful to relieve the metastatic bone pain although cytotoxic chemotherapy should be given for stage IV squamous cell carcinoma of lung.[13,14]

**Anirban Das, Sabyasachi Choudhury1, Sumitra Basuthakur1, Angshuman Mukhopadhyay1**

Departments of Pulmonary Medicines, Murshidabad Medical College, Berhampore, 1Medical College, Kolkata, West Bengal, India
E-mail: dranirbandas_chest@rediffmail.com

**REFERENCES**

1. Fergusson RJ. Lung cancer. In: Seaton A, Seaton D, Leitch AG editors. Crofton and Douglas’s Respiratory Diseases. 5th ed. Vol. 2. Oxford: Blackwell Science Ltd; 2000. p. 1077-122.
2. Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: Symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 2003;123 Suppl 1:975-1045.
3. Utzschneider S, Wicherek E, Weber P, Schmidt G, Jansson V, Dürr HR. Surgical treatment of bone metastases in patients with lung cancer. Int Orthop 2011;35:731-6.
4. Jacofsky DJ, Frassica DA, Frassica FJ. Metastatic disease to bone. Hosp Physician 2004;39:21-8.
5. Patel SR, Benjamin RS. Soft tissue and bone sarcomas and bone metastases. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill Professional; 2008. pp. 610-3.
6. Ecker RD, Endo T, Wieten NM, Krauss WE. Diagnosis and treatment of vertebral column metastases. Mayo Clin Proc 2005;80:1177-86.
7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
8. Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 2008;466:729-36.
9. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-17.
10. Oliver TB, Bhat R, Kellett CF, Adamson DJ. Diagnosis and management of bone metastases. J R Coll Physicians Edinb 2011;41:330-8.
11. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Radionuclide bone imaging: An illustrative review. Radiographics 2003;23:341-58.
12. Fokkema MI, de Heide LJ, van Schelven WD, Hamdy NA. Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer. Neth J Med 2005;63:34-7.
13. Lutz S, Berk L, Chung E, Chow E, Hahn C, Hoskin P, et al. American Society for Radiation Oncology (ASTRO). Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965-76.
14. Saad F. New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treat Rev 2008;34:183-92.